RESUMO
OBJECTIVE: The purpose of this study was to provide gestational age (GA) specific reference ranges for 2-dimensional (2D) placental biometry and 3-dimensional (3D) placental volume between 11 and 14 weeks of gestation. METHODS: Placental biometry including 2D and 3D variables was calculated in 1142 first-trimester singleton pregnancies with non-complicated outcome between September 2016 and February 2020. Ultrasound datasets were obtained at the time of the first-trimester ultrasound, and 2D basal plate (BP), chorionic plate (CP), placental thickness (PT), and 3D placental volume (PV) were measured following a standardized methodology. Reference ranges for each variable were calculated according to GA and crown-rump-length (CRL). RESULTS: A total of 1142 uncomplicated pregnancies were considered for analysis. All placental measurements increased significantly between 11 and 14 weeks, especially for PT (39.64%) and PV (64.4%). Reference ranges were constructed for each 2D and 3D first-trimester placental variable using the best-fit regression model for the predicted mean and SD as a function of GA and CRL. CONCLUSIONS: Reference ranges of 2D placental biometry and 3D placental volume between 11 and 14 weeks of gestation were constructed, generating reference values. Placental biometry showed a progressive increase during the first trimester. This highlights the importance of using reference range charts according to GA.
RESUMO
OBJECTIVES: This study aimed to investigate the impact of levonorgestrel 13.5 mg and Nova T copper 380 mm2 intrauterine devices (LNG13.5-IUD and Cu380-IUD, respectively) on health-related quality of life (HRQoL) and the satisfaction with the method throughout 3 years of use. STUDY DESIGN: We conducted a single-center, evaluator-masked, randomized controlled trial to compare the bleeding profile of LNG13.5-IUD and Cu380-IUD users. Secondary objectives included HRQoL and satisfaction throughout the study. We used the validated questionnaire of the Spanish Society of Contraception (SEC-QoL), which evaluates social, sexual/psychological well-being, and menstrual/breast symptoms, to assess HRQoL and a 5-point Likert scale for satisfaction. RESULTS: These secondary outcomes were assessed in the whole population included in the study: 55 LNG13.5-IUD and 51 Cu380-IUD users. The mean overall SEC-QoL scores were similar at baseline (61.5 and 59.6, respectively; p = 0.570) and greater for LNG13.5-IUD after 3 years (69.2 vs 52.5, respectively; p = 0.002). All SEC-QoL domains scored also higher (p < 0.05 vs Cu380-IUD for all). At month 36, 20/30 (67%) and 8/28 (29%) users, respectively, had reached the MID (a 3.4-point increase) in SEC-QoL score (p = 0.004). At this time, 24/29 (82%) and 9/28 (32%) users, respectively, were "very satisfied" (p < 0.001). Willingness to continue the method was similar (22/28 [79%] vs 17/28 [61%] users, respectively; p = 0.170). CONCLUSIONS: Among the use of LNG13.5-IUD was associated with better HRQoL vs Cu380-IUD throughout the 3 years. Satisfaction with the method was higher with LNG13.5-IUD. IMPLICATIONS: People considering having an LNG13.5-IUD or a Cu380-IUD inserted may now benefit from the information regarding the impact of these devices on HRQoL and satisfaction with the method as reported in our study conducted in Spain.
Assuntos
Dispositivos Intrauterinos de Cobre , Dispositivos Intrauterinos Medicados , Feminino , Humanos , Levanogestrel , Cobre , Qualidade de Vida , Satisfação PessoalRESUMO
OBJECTIVE: To assess the bleeding profiles of the levonorgestrel 13.5 mg intrauterine device (LNG13.5-IUD) and Nova T copper 380 mm2 IUD (Cu380-IUD). STUDY DESIGN: Single-center, evaluator-masked, randomized study conducted in women aged 18-45 years starting these methods. Primary outcomes were number of bleeding days, self-reported bleeding intensity, Pictorial Blood Assessment Chart (PBAC) score, and blood biochemical values at baseline, months 3, 6, 12, 24, and 36 per 90-day reference periods except for PBAC (months). Secondary objectives were presence/duration/intensity of dysmenorrhea and tolerability. RESULTS: We included 106 women aged 32.5 ± 6.7 years: 55 with LNG13.5-IUD and 51 with Cu380-IUD. Data for LNG13.5-IUD versus Cu380-IUD at baseline and month 36 (both respectively) were as follows: (1) median (25th; 75th percentile) number of bleeding days: 12 (9.0; 15.0) versus 12 (9.0; 15.0), p = 0.82, and 4 (0; 13.7) versus 15 (14.2; 20.0), p < 0.001; (2) mean bleeding intensity: 1.7 for both, p = 0.66, and 0.7 and 2.2, p < 0.001. Forty percent versus 0% presented with amenorrhea at month 36; (3) mean PBAC score (95% Confidence interval (CI): 50.7 (16.6; 84.7) versus 130.4 (95.7; 165.0) at month 1, and 7.9 (-26.7; 42.6) versus 126 (90.7; 161.2), p < 0.001; (4) median (25th; 75th percentile) ferritin levels (Ug/L) 33 (19; 53) versus 30 (19; 45), p = 0.70, and 59 (42; 84) versus 21 (8; 39). We did not observe changes or differences between groups in hemoglobin and hematocrit. The duration and intensity of dysmenorrhea were significantly lower with LNG13.5-IUD versus Cu380-IUD. Adverse events were those expected. CONCLUSIONS: LNG13.5-IUD is associated with a significant reduction in blood loss and dysmenorrhea compared with Cu380-IUD. IMPLICATIONS: Women eligible for a levonorgestrel 13.5 mg intrauterine device (IUD) or a copper 380 mm2 IUD should be informed of the differences in bleeding profiles-one of the main causes for IUD discontinuation-so they can compare this information against their bleeding expectations.
Assuntos
Anticoncepcionais Femininos , Dismenorreia , Dispositivos Intrauterinos de Cobre , Dispositivos Intrauterinos Medicados , Feminino , Humanos , Anticoncepcionais Femininos/efeitos adversos , Anticoncepcionais Femininos/farmacologia , Cobre , Dismenorreia/etiologia , Dispositivos Intrauterinos de Cobre/efeitos adversos , Dispositivos Intrauterinos Medicados/efeitos adversos , Levanogestrel/efeitos adversos , Adulto , Distúrbios Menstruais/etiologia , Menstruação/efeitos dos fármacosRESUMO
Chemicals are part of our daily lives, and we are exposed to numerous chemicals through multiple pathways. Relevant scientific evidence contributing to the regulation of hazardous chemicals require a holistic approach to assess simultaneous exposure to multiple compounds. Biomonitoring provides an accurate estimation of exposure to chemicals through very complex and costly sampling campaigns. Finding efficient proxies to predict the risk of chemical exposure in humans is an urgent need to cover large areas and populations at a reasonable cost. We conducted an exploratory study to characterize the human chemical exposome in maternal blood and placenta samples of a population-based birth cohort in Barcelona (2018-2021). Ultimate HRMS-based approaches were applied including wide-scope target, suspect, and nontarget screening. Forty-two chemicals were identified including pesticides, personal care products, or industrial compounds, among others, in the range of ng/mL and ng/g. In parallel, sewage sludge from the wastewater treatment plants serving the residence areas of the studied population were also screened, showing correlations with the type and concentrations of chemicals found in humans. Our findings were suggestive for the potential use of sewage sludge as a proxy of the human exposure and its application in early warning systems to prevent bioaccumulation of hazardous chemicals.
RESUMO
Pregnancy induces a number of immunological, hormonal, and metabolic changes that are necessary for the mother to adapt her body to this new physiological situation. The microbiome of the mother, the placenta and the fetus influence the fetus growth and undoubtedly plays a major role in the adequate development of the newborn infant. Hence, the microbiome modulates the inflammatory mechanisms related to physiological and pathological processes that are involved in the perinatal progress through different mechanisms. The present review summarizes the actual knowledge related to physiological changes in the microbiota occurring in the mother, the fetus, and the child, both during neonatal period and beyond. In addition, we approach some specific pathological situations during the perinatal periods, as well as the influence of the type of delivery and feeding.
Assuntos
Bactérias/classificação , Feto/microbiologia , Microbiota , Placenta/microbiologia , Feminino , Humanos , Recém-Nascido , GravidezRESUMO
En el presente artículo se estudia el impacto que produce en los padres el diagnóstico de una cardiopatía congénita en uno de los hijos durante el embarazo. Estas familias se encuentran en una nueva etapa del ciclo de la vida que implica distintos cambios, cuando los padres reciben el diagnóstico aparecen distintas reacciones que se han de saber gestionar para poder tener una buena evolución y aceptar la situación y las posibles consecuencias posteriores. En el estudio han participado 20 madres con fetos diagnosticados de una cardiopatía congénita y sus parejas. Los instrumentos utilizados han sido el FACES-III, el DAS, el BSI-18 y una entrevista semiestructurada durante la 20-40 semana de gestación. Los resultados muestran que las parejas tienden a tener puntuaciones altas en malestar psicológico y un ajuste diádico idealizado, aunque muestren unas dinámicas familiares moderadas mayoritariamente (45% en los padres y 40% en las madres)
In this article, we studied the impact relationships in parents who have received a prenatal diagnosis of congenital heart disease. These families are in a new stage in the life cycle that involves several changes, when parents receive the diagnosis arise many reactions that they have to manage to have a good evolution and accept the situation and the consequences that can be appear. In the investigation, 20 couples participate with their fetuses are diagnosed with a congenital heart disease. The instruments used were the FACES-III, the DAS, the BSI-18 and a semi-structured interview, which were administered between 20th-40th weeks of gestation. Results shows that couples tend to have high scores on psychological distress and idealized dyadic adjustment, but family dynamics have mostly moderate (45% of parents and 40% of mothers)
Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Adulto Jovem , Adulto , Diagnóstico Pré-Natal , Cardiopatias Congênitas/diagnóstico , Cardiopatias Congênitas/psicologia , Pais/psicologia , Atitude Frente a SaúdeRESUMO
Low oxygen concentration (hypoxia) is part of normal embryonic development, yet the situation is complex. Oxygen (O2 ) is a janus gas with low levels signaling through hypoxia-inducible transcription factor (HIF) that are required for development of fetal and placental vasculature and fetal red blood cells. This results in coupling of fetus and mother around midgestation as a functional feto-placental unit (FPU) for O2 transport, which is required for continued growth and development of the fetus. Defects in these processes may leave the developing fetus vulnerable to O2 deprivation or other stressors during this critical midgestational transition when common septal and conotruncal heart defects (CHDs) are likely to arise. Recent human epidemiological and case-control studies support an association between placental dysfunction, manifest as early onset pre-eclampsia (PE) and increased serum bio-markers, and CHD. Animal studies support this association, in particular those using gene inactivation in the mouse. Sophisticated methods for gene inactivation, cell fate mapping, and a quantitative bio-reporter of O2 concentration support the premise that hypoxic stress at critical stages of development leads to CHD. The secondary heart field contributing to the cardiac outlet is a key target, with activation of the un-folded protein response and abrogation of FGF signaling or precocious activation of a cardiomyocyte transcriptional program for differentiation, suggested as mechanisms. These studies provide a strong foundation for further study of feto-placental coupling and hypoxic stress in the genesis of human CHD.
Assuntos
Hipóxia/embriologia , Troca Materno-Fetal/fisiologia , Oxigênio/metabolismo , Animais , Estudos de Casos e Controles , Modelos Animais de Doenças , Feminino , Feto/fisiopatologia , Idade Gestacional , Cardiopatias Congênitas/etiologia , Humanos , Hipóxia/metabolismo , Hipóxia/fisiopatologia , Camundongos , Oxigênio/fisiologia , Placenta/metabolismo , Placenta/fisiopatologia , Placentação/fisiologia , Pré-Eclâmpsia/etiologia , Gravidez , Cuidado Pré-Natal , Ratos , Transdução de SinaisRESUMO
Pre-eclampsia belongs to a group of obstetric complications that are closely related through placental insufficiency, which also includes intrauterine growth restriction and placental abruption. Timely and accurate detection and treatment of pre-eclampsia is usually difficult, since diagnostic criteria are still based on nonspecific signs and symptoms and there is no clear association between the usual criteria for severity and unfavorable outcomes for mother and fetus. The discovery of the role of angiogenic factors (sFlt-1 y PlGF) in the pathophysiology of placental insufficiency is a key step toward improving early diagnosis and establishing a prognosis in cases occurring before week 34 of pregnancy. At present, ≤ 38 is widely accepted to be threshold value of the sFlt-1/PlGF ratio that rules out suspected pre-eclampsia. The use of the ratio is considered cost-effective. However, current data on the treatment and prognosis of women with an abnormally high sFlt1/PlGF ratio are more limited. The present article summarizes current knowledge on the clinical application of the sFlt-1/PlGF for the diagnosis and prognosis of pre-eclampsia and highlights those areas that should be addressed with respect to biomarkers, for example, their role as targets in the development and follow-up of new treatments
La preeclampsia pertenece a un grupo de complicaciones obstétricas estrechamente relacionadas entre ellas por la existencia de una insuficiencia placentaria, que incluye también la restricción del crecimiento intrauterino y el desprendimiento placentario. El reconocimiento y tratamiento oportuno y preciso de la preeclampsia suele ser difícil, ya que los criterios diagnósticos aún se basan en signos y síntomas inespecíficos y no existe una relación clara entre los criterios habituales de gravedad y los resultados desfavorables para la madre o el feto. El descubrimiento del papel que juegan los factores relacionados con la angiogénesis (sFlt-1 y PlGF) en la fisiopatología subyacente de la insuficiencia placentaria ha constituido un paso importante a la hora de mejorar el diagnóstico precoz y establecer un pronóstico en los casos que se presentan antes de la semana 34 de gestación. En la actualidad está ampliamente aceptado que el valor límite del cociente sFlt-1/PlGF que permite excluir la existencia de preeclampsia en pacientes en las que se sospecha esta enfermedad es de 38 o menos, y que el uso de este cociente resulta costo-eficiente. Sin embargo, los datos disponibles relativos al tratamiento y al pronóstico de las mujeres con niveles anormalmente altos del cociente sFlt1/PlGF son más limitados. Este artículo resume los conocimientos actuales relativos a la aplicación clínica del cociente sFlt-1/PlGF para diagnosticar y pronosticar el curso de la preeclampsia, y señala las próximas tareas que serán necesarias abordar en relación con estos biomarcadores, como por ejemplo el papel que pueden jugar como dianas para el desarrollo y el seguimiento de nuevos tratamientos
Assuntos
Humanos , Feminino , Gravidez , Pré-Eclâmpsia/diagnóstico , Prognóstico , Receptor 1 de Fatores de Crescimento do Endotélio Vascular/sangue , Insuficiência Placentária/diagnóstico , Biomarcadores/análise , Insuficiência Placentária/terapia , Insuficiência Placentária/prevenção & controle , Proteínas de Membrana/sangueRESUMO
INTRODUCCIÓN: La restricción del crecimiento intrauterino (RCIU) y la prematuridad se han asociado con una mayor morbimortalidad perinatal, así como con una reprogramación fetal a nivel cardiovascular. Sin embargo, son escasos los estudios sobre el impacto de la RCIU de causa placentaria en los resultados perinatales y en biomarcadores cardiovasculares de recién nacidos prematuros. OBJETIVOS: Determinar las diferencias en morbimortalidad neonatal y biomarcadores de disfunción cardiovascular en sangre de cordón entre prematuros con RCIU de origen placentario y sin RCIU, así como estudiar su relación con la gravedad de la RCIU según el estudio Doppler fetal. MATERIAL Y MÉTODOS: Estudio prospectivo de cohortes: prematuros con RCIU de causa placentaria y prematuros sin RCIU adecuadamente apareados. Clasificación de la gravedad de la RCIU según el Doppler. Análisis comparativo de resultados perinatales, de morbimortalidad neonatal y de niveles en sangre de cordón de biomarcadores de disfunción cardiovascular. RESULTADOS: Los prematuros con RCIU presentan un menor peso, longitud, perímetro craneal y Apgar al nacimiento, así como un aumento de la morbilidad neonatal y de los niveles de biomarcadores de disfunción cardiovascular, comparado con los prematuros sin RCIU. Estas diferencias aumentan con la gravedad de la RCIU determinada por el estudio hemodinámico Doppler prenatal. CONCLUSIONES: Los prematuros afectados de RCIU de causa placentaria presentan un incremento de la morbimortalidad neonatal independiente de la prematuridad, que aumenta de forma estadísticamente significativa con la gravedad de la RCIU. La afectación placentaria y su gravedad también determinan la alteración de biomarcadores de disfunción cardiovascular al nacimiento
INTRODUCTION: Intrauterine growth restriction (IUGR) and prematurity have been associated with increased perinatal morbidity and mortality and also with cardiovascular foetal programming. However, there are few studies on the impact of placenta-related IUGR on perinatal outcomes and cardiovascular biomarkers in pre-term infants. OBJECTIVES: To determine differences in neonatal morbidity, mortality and cord blood biomarkers of cardiovascular dysfunction between pre-term placenta-related IUGR and non-IUGR new-borns, and to analyse their relationship with the severity of IUGR according to foetal Doppler evaluation. MATERIAL AND METHODS: Prospective cohort study: pre-term infants with placenta-related IUGR and matched pre-term infants without IUGR. A Doppler scan was performed, and placenta- IUGR was classified according to severity. Comparative analysis of perinatal outcomes, neonatal morbidity and mortality, and cord blood levels of biomarkers of cardiovascular dysfunction was performed. RESULTS: IUGR new-borns present lower weight, length, head circumference, and Apgar score at birth, as well as increased neonatal and cardiovascular dysfunction biomarker levels, compared with pre-term new-borns without IUGR. These differences increase with the severity of IUGR determined by prenatal umbilical artery Doppler scan. CONCLUSIONS: Placenta-related-IUGR pre-term infants, irrespective of gestational age, present increased neonatal morbidity and mortality that is significantly proportional to the severity of IUGR. Placental impairment and severity also determine levels of cardiovascular dysfunction biomarkers at birth
Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Gravidez , Retardo do Crescimento Fetal , Cardiopatias/epidemiologia , Insuficiência Placentária , Mortalidade Infantil , Recém-Nascido Prematuro , Indicadores de Morbimortalidade , Ecocardiografia Doppler , Estudos ProspectivosRESUMO
INTRODUCTION: Intrauterine growth restriction (IUGR) and prematurity have been associated with increased perinatal morbidity and mortality and also with cardiovascular foetal programming. However, there are few studies on the impact of placenta-related IUGR on perinatal outcomes and cardiovascular biomarkers in pre-term infants. OBJECTIVES: To determine differences in neonatal morbidity, mortality and cord blood biomarkers of cardiovascular dysfunction between pre-term placenta-related IUGR and non-IUGR new-borns, and to analyse their relationship with the severity of IUGR according to foetal Doppler evaluation. MATERIAL AND METHODS: Prospective cohort study: pre-term infants with placenta-related IUGR and matched pre-term infants without IUGR. A Doppler scan was performed, and placenta-IUGR was classified according to severity. Comparative analysis of perinatal outcomes, neonatal morbidity and mortality, and cord blood levels of biomarkers of cardiovascular dysfunction was performed. RESULTS: IUGR new-borns present lower weight, length, head circumference, and Apgar score at birth, as well as increased neonatal and cardiovascular dysfunction biomarker levels, compared with pre-term new-borns without IUGR. These differences increase with the severity of IUGR determined by prenatal umbilical artery Doppler scan. CONCLUSIONS: Placenta-related-IUGR pre-term infants, irrespective of gestational age, present increased neonatal morbidity and mortality that is significantly proportional to the severity of IUGR. Placental impairment and severity also determine levels of cardiovascular dysfunction biomarkers at birth.
Assuntos
Retardo do Crescimento Fetal , Cardiopatias/epidemiologia , Insuficiência Placentária , Feminino , Humanos , Recém-Nascido , Recém-Nascido Prematuro , Masculino , Gravidez , Estudos Prospectivos , Índice de Gravidade de DoençaRESUMO
OBJECTIVE: Intrauterine-growth restriction is associated with impaired neurodevelopment. However, studies on early childhood neurodevelopment of premature infants with placenta-related intrauterine-growth restriction (IUGR) are scarce and heterogeneous. We aimed to analyze the impact of placenta-related IUGR on preschool age neurodevelopment in preterm infants, and to ascertain which prenatal and postnatal factors influence neurodevelopment in these infants. METHODS: Prospective cohorts study: 48 placenta-related IUGR premature infants and 25 matched non-IUGR premature infants (mean gestational age: 31.4 and 31.6 weeks, respectively). Preschool neurodevelopment assessment with cognitive Bayley Scales III and with ASQ-III surveys (age interval: 34.07-42.50 months). Inter-cohort result comparison. Analysis of perinatal and environmental factors associated with impaired neurodevelopment in both cohorts. RESULTS: No statistically significant neurodevelopment differences were observed at preschool age between both preterm cohorts. Multivariate analysis of perinatal and environmental factors showed daycare, breastfeeding, higher parental educational level, and absence of severe neonatal morbidity to be associated with a lower risk of altered neurodevelopment at preschool age. CONCLUSIONS: Placenta-related IUGR does not have a significant impact on preschool neurodevelopment in our preterm patients. Instead, post-natal positive environmental factors such as parental educational level, breastfeeding, and daycare attendance make a difference towards an improvement in neurodevelopment in these infants.
Assuntos
Deficiências do Desenvolvimento/prevenção & controle , Retardo do Crescimento Fetal , Recém-Nascido Prematuro/crescimento & desenvolvimento , Aleitamento Materno , Creches , Pré-Escolar , Estudos de Coortes , Escolaridade , Feminino , Seguimentos , Humanos , Recém-Nascido , Testes Neuropsicológicos , Cuidado Pós-Natal , GravidezRESUMO
Background and Objective: The aim was to evaluate the role of anti-annexin A5 (anti-ANXA5) antibodies as risk factor for recurrent miscarriage (RM) and unexplained fetal loss (UFL). Patients and methods: Retrospective, cohort study. Setting: Vall dHebron University Hospital. Subjects: 122 women, in two groups: Study group: 54 women with RM/UFL and control group: 68 pregnant without RM/UFL. Intervention: Antiphospholipid, mainly anti-ANXA5 antibody analysis. Comparison of all antiphospholipid antibodies between groups. Results: Antiphospholipid antibody (aPL) prevalence in the study group was 10/54 (14.8%) and 5/68 (7.3%) in control group (p=0.09). In the RM subgroup, it was 3/25 and 9/34 in UFL versus 5/68 in controls (p=0.013). Lupus anticoagulant (LA) was present in 4 cases, all belonging to the study group (p=0.011). Four out of 34 women with UFL were positive for anticardiolipin antibodies-IgG (IgG-aCL) versus 1/68 in controls (p=0.041). In RM subgroup, anti-ANXA5 antibodies were positive in 2/25 versus 3/68 in controls, and in UFL subgroup, 3/34 versus 3/68 cases (p=1.000). Conclusion: According to our results, anti-ANXA5 antibodies should not be considered as a risk factor for RM/UFL (AU)
Fundamento y Objetivo: El objetivo principal fue evaluar el papel de los anticuerpos anti-anexina A5 (ac-anti-ANXA5) como factor de riesgo de abortos recurrentes (AR) y de la pérdida fetal inexplicada (PFI). Pacientes y Método: Se trata de un estudio de cohortes retrospectivo. Se desarrolló en el Hospital Universitario Vall dHebron de Barcelona. Se estudiaron un total de 122 mujeres, en dos grupos: grupo de estudio, formado por: 54 mujeres con AR/PFI y grupo control, constituido por 68 gestantes sin historia de AR/PFI. Se estudiaron los anticuerpos antifosfolípido (aFL), con especial interés para los ac-anti-ANXA5. Se compararon los resultados entre ambos grupos, estudio y control. Resultados: La prevalencia de positividad para los aFL fue de 10/54 (14,8%) en el grupo de estudio y de 5/68 (7,3%) en el grupo control (p=0,09). En el subgrupo de mujeres con AR, la prevalencia de los aFL fue de 3/25 y de 9/35 en el subgrupo afecto de PFI, versus 5/68 en el grupo control (p=0,013). El anticoagulante lúpico (AL) fue positivo en 4 casos, todos ellos pertenecientes al grupo de estudio (p=0,011). Cuatro de las 34 mujeres con historia de PFI tenían anticuerpos anti-cardiolipina isotipo IgG versus 1/68 en el grupo control (p=0,041). En el subgrupo de AR, los ac-anti-anexina A5 se detectaron en 2/25 casos versus 3/68 en el grupo control y 3/34 el subgrupo con PFI (p=1,000). Conclusiones: De acuerdo con los resultados de nuestro estudio, los anticuerpos anti-anexina A5 no deberían ser considerados como factores de riesgo de AR y/o de PFI (AU)
Assuntos
Humanos , Feminino , Gravidez , Adulto , Aborto Espontâneo/imunologia , Anexina A5/imunologia , Anticorpos Antifosfolipídeos/sangue , Síndrome Antifosfolipídica/imunologia , Estudos de Coortes , Estudos Retrospectivos , Inibidor de Coagulação do LúpusRESUMO
BACKGROUND AND OBJECTIVE: The aim was to evaluate the role of anti-annexin A5 (anti-ANXA5) antibodies as risk factor for recurrent miscarriage (RM) and unexplained fetal loss (UFL). PATIENTS AND METHODS: Retrospective, cohort study. SETTING: Vall d'Hebron University Hospital. SUBJECTS: 122 women, in two groups: STUDY GROUP: 54 women with RM/UFL and control group: 68 pregnant without RM/UFL. INTERVENTION: Antiphospholipid, mainly anti-ANXA5 antibody analysis. Comparison of all antiphospholipid antibodies between groups. RESULTS: Antiphospholipid antibody (aPL) prevalence in the study group was 10/54 (14.8%) and 5/68 (7.3%) in control group (p=0.09). In the RM subgroup, it was 3/25 and 9/34 in UFL versus 5/68 in controls (p=0.013). Lupus anticoagulant (LA) was present in 4 cases, all belonging to the study group (p=0.011). Four out of 34 women with UFL were positive for anticardiolipin antibodies-IgG (IgG-aCL) versus 1/68 in controls (p=0.041). In RM subgroup, anti-ANXA5 antibodies were positive in 2/25 versus 3/68 in controls, and in UFL subgroup, 3/34 versus 3/68 cases (p=1.000). CONCLUSION: According to our results, anti-ANXA5 antibodies should not be considered as a risk factor for RM/UFL.
Assuntos
Aborto Espontâneo/imunologia , Anexina A5/imunologia , Anticorpos Antifosfolipídeos/sangue , Síndrome Antifosfolipídica , Síndrome Antifosfolipídica/imunologia , Estudos de Coortes , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Inibidor de Coagulação do Lúpus , Gravidez , Prevalência , Estudos Retrospectivos , Fatores de RiscoRESUMO
PROBLEM: Anti-beta(2)-Glicoprotein-1 antibodies (anti-beta(2)GPI-ab) have been related to recurrent miscarriage (RM) with conflicting results. The aim was to evaluate the role of anti-beta(2)-GPI-ab as unique biological marker in RM related to antiphospholipid (aPL). METHOD OF STUDY: A cohort study that included 59 cases, divided in two groups, was designed: group 1 comprised 43 pregnant women with 'obstetric' antiphospholipid syndrome (APS) and group 2 included 16 cases with similar complaints but only having repeatedly anti-beta(2)-GPI-ab. Previous thrombosis and/or inherited thrombophilia were excluded. Lupus anticoagulant, anticardiolipin antibodies (aCA), anti-beta(2)-GPI-ab, and other autoantibodies were analyzed. Miscarriages, premature births, pre-eclampsia, live births, placental and systemic thromboses were studied. RESULTS: No differences in previous obstetric complications were detected (P = 1.00-0.164). After the treatment, differences in number of obstetric complications were not seen (P = 1.00). Live births were similar in two groups (88.4% and 93.7%; P = 1.00). Placental thrombosis was equal in both groups, 93.3% versus 80% (P = 1.00). CONCLUSION: These results suggest that anti-beta(2)-GPI-ab may be considered a biological marker for obstetric APS.